JP2014523445A - 前立腺癌を処置するための新規な組成物及び方法 - Google Patents

前立腺癌を処置するための新規な組成物及び方法 Download PDF

Info

Publication number
JP2014523445A
JP2014523445A JP2014521743A JP2014521743A JP2014523445A JP 2014523445 A JP2014523445 A JP 2014523445A JP 2014521743 A JP2014521743 A JP 2014521743A JP 2014521743 A JP2014521743 A JP 2014521743A JP 2014523445 A JP2014523445 A JP 2014523445A
Authority
JP
Japan
Prior art keywords
composition
compound
solid dispersion
solid
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014521743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523445A5 (enExample
Inventor
ケースビアー，デイビッド，スコット
センティッシ，アブデラ
モアトン，リチャード，クリスチャン
ターンブル，マーク
Original Assignee
トーカイ ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トーカイ ファーマシューティカルズ，インク． filed Critical トーカイ ファーマシューティカルズ，インク．
Publication of JP2014523445A publication Critical patent/JP2014523445A/ja
Publication of JP2014523445A5 publication Critical patent/JP2014523445A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014521743A 2011-07-18 2012-07-18 前立腺癌を処置するための新規な組成物及び方法 Pending JP2014523445A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161508823P 2011-07-18 2011-07-18
US61/508,823 2011-07-18
PCT/US2012/047253 WO2013012959A1 (en) 2011-07-18 2012-07-18 Novel compositions and methods for treating prostate cancer

Publications (2)

Publication Number Publication Date
JP2014523445A true JP2014523445A (ja) 2014-09-11
JP2014523445A5 JP2014523445A5 (enExample) 2015-09-03

Family

ID=47558457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521743A Pending JP2014523445A (ja) 2011-07-18 2012-07-18 前立腺癌を処置するための新規な組成物及び方法

Country Status (8)

Country Link
US (3) US20140288037A1 (enExample)
EP (1) EP2734207A4 (enExample)
JP (1) JP2014523445A (enExample)
CN (1) CN103813794A (enExample)
AU (1) AU2012284053A1 (enExample)
BR (1) BR112014001440A2 (enExample)
CA (1) CA2841960A1 (enExample)
WO (1) WO2013012959A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534320A (ja) * 2017-09-22 2020-11-26 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー アビラテロン環状オリゴマー薬学的製剤ならびにその形成法および投与法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008098244A1 (en) 2007-02-09 2008-08-14 Metabasis Therapeutics, Inc. Novel antagonists of the glucagon receptor
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CN104803891B (zh) 2008-08-13 2017-10-20 症变治疗公司 胰高血糖素拮抗剂
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014138881A1 (en) * 2013-03-12 2014-09-18 Patheon, Inc. Drug delivery system
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
EP2969227B1 (en) * 2013-03-15 2019-05-08 Iceutica Inc. Abiraterone acetate formulation
US9694005B2 (en) * 2013-04-04 2017-07-04 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
EP3033088A4 (en) * 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10045998B2 (en) 2013-12-12 2018-08-14 Basf Se Solid form of abiraterone acetate
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
US9937259B2 (en) * 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
EP3203992A4 (en) * 2014-10-08 2018-11-07 Boston Biopharm, Inc. Compositions and methods for increasing the bioavailability of one or more compounds
CN105616365B (zh) * 2014-11-08 2019-04-05 山东新时代药业有限公司 一种依维莫司片剂
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
WO2016172517A1 (en) * 2015-04-24 2016-10-27 Tokai Pharmaceuticals, Inc. Methods of treating prostate cancer
US10550107B2 (en) 2015-05-18 2020-02-04 Msn Laboratories Private Limited Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN106692051B (zh) * 2015-08-18 2021-01-12 南京诺瑞特医药科技有限公司 17-（3-吡啶）雄甾-4,6-二烯-3-酮的制剂
CN105055314A (zh) * 2015-09-28 2015-11-18 杭州安德科技有限公司 一种阿比特龙的口腔喷雾剂及其使用和制备方法
US10682362B2 (en) 2015-10-14 2020-06-16 Wayne State University Treatments and diagnostics for cancers
CN109125276A (zh) * 2017-06-19 2019-01-04 齐鲁制药有限公司 一种醋酸阿比特龙片剂的药物组合物及其制备方法
WO2019042247A1 (zh) * 2017-08-28 2019-03-07 江苏恒瑞医药股份有限公司 一种cyp17抑制剂的药物组合物及其制备方法
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
CN109956990B (zh) * 2017-12-22 2023-02-17 四川科瑞德制药股份有限公司 一种干燥哌库溴铵的方法
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
PL247245B1 (pl) * 2019-01-31 2025-06-02 Gdanski Univ Medyczny Samoemulgująca kompozycja farmaceutyczna w postaci ciekłej zawierająca jako substancję aktywną substancję leczniczą nietrwałą w środowisku wodnym
CN110917152B (zh) * 2019-02-01 2021-07-02 鲁南制药集团股份有限公司 一种cyp17抑制剂片及其制备方法
CZ2019168A3 (cs) 2019-03-20 2020-09-30 Zentiva, K.S. Farmaceutická kompozice obsahující abirateron acetát
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
EP4057996B1 (en) * 2019-11-14 2023-07-12 Suven Life Sciences Limited Amorphous pharmaceutical compositions of abiraterone acetate
MX2022013043A (es) * 2020-04-16 2023-01-24 Tavanta Therapeutics Hungary Incorporated Metodos y composiciones para tratar el cancer de prostata.
TWI828471B (zh) 2021-12-15 2024-01-01 大陸商湖南慧澤生物醫藥科技有限公司 醋酸阿比特龍的自微乳組合物和應用
EP4608841A1 (en) * 2022-10-25 2025-09-03 University of Maryland, Baltimore Salts of galeterone and salts of next generation galeterone analogs, and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521963A (ja) * 2001-10-15 2004-07-22 アストラゼネカ・ユーケイ・リミテッド 医薬製剤
US20080249076A1 (en) * 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2011017534A2 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
WO1999052931A1 (fr) * 1998-04-10 1999-10-21 Mitsubishi Chemical Corporation Dispersion solide contenant un derive d'acide sialique
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US20060013873A1 (en) * 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
PT2206719E (pt) * 2005-03-02 2015-02-05 Univ Maryland Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
WO2010089763A2 (en) * 2008-06-30 2010-08-12 Reliance Life Sciences Pvt. Ltd. Poly(n-vinyl caprolactam-co-acrylamide) microparticles for controlled release applications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521963A (ja) * 2001-10-15 2004-07-22 アストラゼネカ・ユーケイ・リミテッド 医薬製剤
US20080249076A1 (en) * 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2011017534A2 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYAN,C.J. ET AL, JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 9, JPN6016017632, 2010, pages 1481 - 1488, ISSN: 0003316198 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534320A (ja) * 2017-09-22 2020-11-26 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー アビラテロン環状オリゴマー薬学的製剤ならびにその形成法および投与法

Also Published As

Publication number Publication date
EP2734207A1 (en) 2014-05-28
US20160002283A1 (en) 2016-01-07
WO2013012959A1 (en) 2013-01-24
US20140288037A1 (en) 2014-09-25
AU2012284053A1 (en) 2014-01-23
BR112014001440A2 (pt) 2017-02-21
US20150320770A1 (en) 2015-11-12
EP2734207A4 (en) 2015-06-17
CA2841960A1 (en) 2013-01-24
CN103813794A (zh) 2014-05-21

Similar Documents

Publication Publication Date Title
US20160002283A1 (en) Novel compositions and methods for treating prostate cancer
JP7238130B2 (ja) 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
TWI482768B (zh) 雜環化合物之非晶質體、含有其之固體分散體、藥劑及其製法
US12171770B1 (en) Bioavailable solid state (17-beta)-hydroxy-4-androsten-3-one esters
KR102606253B1 (ko) 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형
JP2016074687A (ja) 前立腺癌の処置
KR101454086B1 (ko) 이마티닙 메실레이트의 안정화된 무정형 형태
WO2020242935A1 (en) Methods of treatment for cystic fibrosis
JP2003507327A (ja) 化学化合物
CA2672888A1 (en) Methods and formulations for improved bioavailability of antiprogestins
JP7241807B2 (ja) １５β－ヒドロキシ－酢酸オサテロンの結晶多形
JP2022078094A (ja) Ｏｌｉｇ２活性の阻害
JP2003534296A (ja) 溶出性の改善されたプランルカスト固体分散系及びその製造方法
WO2005046697A1 (ja) フェニルアラニン誘導体の徐放性経口投与製剤
KR20230024389A (ko) 우티델론의 고체 경구용 제제
WO2012127495A2 (en) A pharmaceutical composition and process for preparation thereof
CN103145707B (zh) 氢化吡啶[4,3-b]吲哚类化合物的制备方法
KR100816960B1 (ko) 2,5-디메틸-2ｈ-피라졸-3-카르복실산｛2-플루오로-5-[3-((ｅ)-2-피리딘-2-일-비닐)-1ｈ-인다졸-6-일아미노]-페닐｝-아미드의 다형성 및 무정질 형태
CN108779142A (zh) 选择性孕酮受体调节剂(SPRM) (11.β.,17.β.)-17-羟基-11-[4-(甲基磺酰基)苯基]-17-(五氟乙基)雌甾-4,9-二烯-3-酮的前药
CN102040643B (zh) 环索奈德硝酸酯衍生物
CN101830911A (zh) 一类噻吩并吡啶衍生物、其制备方法和用途
JP2022000473A (ja) 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
CN104302275A (zh) 类固醇反应性皮肤病的治疗方法
BR122023016197B1 (pt) Sal cristalino de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida, composição farmacêutica o compreendendo e uso dos mesmos
CN101317848A (zh) 依匹乐酮晶形

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170206